CD93 (AA4.1) Monoclonal Antibody (AA4.1), Biotin, eBioscience™, Invitrogen™

Description

• Description: The AA4.1 monoclonal antibody reacts with mouse C1qRp, an approximately 130-140 kDa C-type lectin-like type I transmembrane protein
• The AA4.1 antigen was originally identified as an antigen expressed on early stages of B cell development in bone marrow
• Adult spleen and fetal liver also have detectable numbers of AA4.1^+ cells
• In combination with other markers of hematopoietic progenitor cells such as Thy-1, Sca-1, c-Kit, CD43, and CD24, the bone marrow Lymphoid-Committed Progenitors (CLP) can be segregated into more primitive and more differentiated subsets based on expression of AA4.1
• Correlated expression of surface IgM (sIgM), CD23, and AA4.1 antigen has also been used to define three nonproliferative subpopulations of immature/transitional peripheral B cells designated: T1 (AA4.1^+/CD23^-/sIgMhi), T2 (AA4.1^+/CD23^+/sIgMhi), and T3 (AA4.1^+/CD23^+/sIgMlo)
• AA4.1 is also reported to be expressed in cytoplasmic vesicles in endothelial cells, megakaryoblasts, and platelets
• It is reported that monoclonal antibodies AA4.1 and 493 recognize different epitopes of the same molecule
• Applications Reported: The AA4.1 antibody has been reported for use in flow cytometric analysis
• Applications Tested: The AA4.1 antibody has been tested by flow cytometric analysis of mouse bone marrow and splenocyte cells
• This can be used at less than or equal to 0.25 μg per test
• The protein encoded by this gene is a cell-surface glycoprotein and type I membrane protein that was originally identified as a myeloid cell-specific marker
• The encoded protein was once thought to be a receptor for C1q, but now is thought to instead be involved in intercellular adhesion and in the clearance of apoptotic cells
• The intracellular cytoplasmic tail of this protein has been found to interact with moesin, a protein known to play a role in linking transmembrane proteins to the cytoskeleton and in the remodelling of the cytoskeleton.